Thalidomide, cyclooxygenase-2, and angiogenesis: potential for therapy

Clin Cancer Res. 2001 Nov;7(11):3311-3.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Angiogenesis Inhibitors / pharmacology*
  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / pharmacology
  • Cyclooxygenase Inhibitors / therapeutic use
  • Humans
  • Isoenzymes / drug effects*
  • Isoenzymes / genetics
  • Isoenzymes / metabolism
  • Membrane Proteins
  • Neoplasms / blood supply
  • Neoplasms / prevention & control
  • Prostaglandin-Endoperoxide Synthases / drug effects*
  • Prostaglandin-Endoperoxide Synthases / genetics
  • Prostaglandin-Endoperoxide Synthases / metabolism
  • Thalidomide / pharmacology*
  • Thalidomide / therapeutic use

Substances

  • Angiogenesis Inhibitors
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Isoenzymes
  • Membrane Proteins
  • Thalidomide
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases